(Q41881498)

13 October 2017

0 references

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma (English)

1 reference

13 October 2017

Enrique Grande

1

1 reference

13 October 2017

Jaume Capdevila

2

1 reference

13 October 2017

Juan José Díez

3

1 reference

13 October 2017

Federico Longo

4

1 reference

13 October 2017

Alfredo Carrato

5

1 reference

13 October 2017

1 July 2013

1 reference

Journal of Research in Medical Sciences

13 October 2017

1 reference

13 October 2017

18

1 reference

13 October 2017

7

1 reference

13 October 2017

623-625

1 reference

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

5 June 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Anaplastic thyroid carcinoma: pathogenesis and emerging therapies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

Sorafenib in metastatic thyroid cancer.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897033

18 August 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/24516498

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

13 October 2017

1 reference